rafivirumab

Names

[ Name ]:
rafivirumab

Biological Activity

[Description]:

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3].

[Related Catalog]:

Research Areas >> Infection

[In Vitro]

Rafivirumab 显示出对一系列 RABV 分离株的中和作用[2]。 Rafivirumab 与 RABV 糖蛋白的抗原位点 I 结合[3]。 Rafivirumab 完全中和野生型 ERA439 和 N336D R346K，EC50 范围在 3 到 5 pg/mL 之间[3]。

[In Vivo]

Rafivirumab (3-12 μg/kg，肌肉注射) 与 CR4098 一起提高了感染蝙蝠狂犬病病毒的叙利亚仓鼠的存活率[2]。 Animal Model: Syrian hamsters infected with bat rabies viruses[2]. Dosage: 6, 12, 16, 18 or 24 μg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio) Administration: i.m. Result: Increased survival rate.

[References]

[1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45.

[2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48.

[3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.